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Background: Lonicera caerulea L. (blueberry honeysuckle, Caprifoliaceae) is a traditional crop in northern Russia, 
China, and Japan. Its fruits are little known as edible berries in North America and Europe. This review deals with 
the botany and chemical composition of L. caerulea and the biological activity of its main constituents, focusing on 
the potential health beneﬁ  ts of the berries.
Methods and Results: PubMed, Science Direct and ISI Web of KnowledgeSM databases were used for this paper. 
Literature sources include the period 1935–2007.
L. caerulea berries a are rich source of phenolic compounds such as phenolic acids as well as anthocyanins, proan-
thocyanidins and other ﬂ  avonoids, which display potential health promoting eﬀ  ects. Chemopreventive, antimicrobial, 
anti-adherence and antioxidant beneﬁ  ts, among others are described for these compounds.
Conclusions: The potential of L. caerulea berries to prevent chronic diseases such as diabetes mellitus, cardiovas-
cular diseases and cancer seems to be related above all to their phenolic content.
INTRODUCTION
Lonicera caerulea L. (blue berry honeysuckle, Capri-
foliaceae) is a traditional crop used in folk medicine in 
northern Russia, China, and Japan but its fruits are little 
known as edible berries in North America and Europe1. 
In recent years a large number of studies have investigated 
the therapeutic eﬀ  ects of various fruits and vegetables in 
the prevention of a range of diseases and there is increas-
ing interest in herbal medicine products. Berries consti-
tute one of the most important sources of potential health 
supporting phytochemicals in the human diet2. They are 
a rich source of ascorbic acid and phenolic compounds, 
particularly phenolic acids, anthocyanins, proanthocya-
nidins and other ﬂ  avonoids. These compounds provide 
the pigmentation of fruits and prove beneﬁ  cial to human 
health3, 4. Their biological activities include: protection 
against the incidence and mortality rates of cancer5, pro-
tection against ischemic heart disease mortality6 and as 
well as they have antitumorigenic7, antimicrobial8, anti-
inlammatory-allergic9 and antimutagenic properties10. 
The aim of this paper was to review the current literature 
on berry-derived biologically active compounds, with the 
focus on L. caerulea. 
1. BOTANICAL DESCRIPTION
The genus Lonicera, which includes almost 180 spe-
cies of deciduous or evergreen shrubs, belongs to the 
Caprifoliaceae family and is native to the Northern 
Hemisphere (Fig. 1) (ref.1). The nomenclature of honey-
suckles is complicated; a lot of species are sometimes clas-
siﬁ  ed as varieties and have many synonyms. Large genetic 
variation is common among the Lonicera genus. For exam-
ple 10 common species of L. involucrata are only hybrids 
of one known origin11. Many species of Caprifoliaceae 
family have non-edible fruits and are cultivated only as 
decorative shrubs or rambling plants12, especially for their 
glorious blooms and ornamental fruits1. The fruit colour, 
which ranges from white or yellow to scarlet or navy blue, 
is used as an indicator of plant maturity1. Honeysuckles 
are also favoured because of their extreme hardiness to 
the cold13. A few species are used in indigenous medicine 
as antipyretic, stomachic, diuretic and antidysenteric in 
India14.
L. caerulea L., also known as blue honeysuckle, honey-
berry, edible honeysuckle or sweet berry honeysuckle15 is 
native to the northern temperate zone, especially Russia 
(Kamchatka Peninsula, Siberia), North Eastern Asia, 
and Japan15, 16. In Europe, it occurs rarely in the Alps 
and Scandinavia3. L. caerulea is currently commercially 
produced in Russia and Japan, but this species was un-
known as an edible berry in North America until very 
recently17. 
Native L. caerulea plants grow from 0.8 to 3.0 m tall, 
but under cultivation the shrubs reach 1.0 m wide to 1.8 m 
tall17. They do not require special soil type; even wet sandy 
or loamy soil is suitable, pH can range from 5 to 7 and 
the organic proportion can be higher12. Plants have strong 164  I. Svarcova, J. Heinrich, K. Valentova
tolerance to severe low-temperature conditions. They can 
survive a temperature of –46 °C without damage17, 18. The 
freezing tolerance of perennial plants increases in fall 
and winter to prevent injury under cold conditions. It is 
known as cold acclimation and seems to be connected 
with the content and accumulation of speciﬁ  c type of 
carbohydrates and proteins (see below). The raﬃ   nose 
family of oligosaccharides have been shown to be poten-
tial cryoprotectants because of their capacity to modify 
the freezing behaviour of aqueous solutions18, 19. Also the 
presence of galactose-containing oligosaccharides strongly 
correlates with increases in freezing, as well as desiccation 
tolerance18. Blue honeysuckle shrubs are long-lived and 
can survive 25 to 30 years12.
Blue honeysuckles are not self-pollinating so at least 
two single plants are required. Fruits become ripe very 
early in May or June in European conditions. The plants 
can begin fruiting within one year after planting and after 
three years almost 500 g of fruits can be acquired from 
one plant12. Fruit shapes are oval to long and dark navy 
blue to purple in color15 with blue waxy coating according 
to the genotype12. They can grow up to more than 2 cm 
long and weigh more than 1.5 g17. Their ﬂ  avour is similar 
to that of bilberries or black currants and it can vary from 
bitter to sweet15.
2.  CONSTITUENTS AND THEIR 
BIOLOGICAL ACTIVITY
L. caerulea berries and their juice contain sac-
charides, lipids, proteins, organic acids and polyphe-
nols as major components and also ascorbic acid 
(45–93 mg · 100 g–1)(ref.15), vitamin B, magnesium, phos-
phorus, calcium and potassium as minor compounds20. 
2.1. Saccharides 
L. caerulea fruit contain 7.20 % saccharides. Free sac-
charides include 3.2 % glucose and 2.9 % fructose, bound 
saccharides are 0.8 % glucose, 0.2 % galactose and 0.1 % 
arabinose21. Five kinds of saccharides have been identiﬁ  ed 
in L. caerulea shoot apices according to Imanishi et al18. 
The content of fructose, glucose, saccharose, raﬃ   nose 
and stachyose varies depending on climatic conditions 
and season. The highest level of sugars has been measured 
in January, and then the saccharide content decreased 
to May and after that increased again. According to the 
literature18 the dominant sugar is saccharose with 50–90 % 
of total saccharides. The content of stachyose and raﬃ   -
nose changes dramatically during the year. While it is neg-
ligible from April to November, it increases rapidly from 
November to March. Fructose and glucose constitute 
only small proportion of total sugars and their content 
does not change over the year. Accumulation of raﬃ   nose 
and/or stachyose has strong relationship to the freezing 
tolerance and desiccation18. L. caerulea leaves comprise 
three glucosides, named caerulosides A, B (Fig. 2) and C. 
These compounds are formed from secologanin attached 
through acetal bonds to C-4'and C-6' of the saccharide 
part of loganin and sweroside, respectively. Caerulosides 
are the ﬁ  rst bis-iridoids, that are composed of two units 
of iridoids bound by acetal linkages22, 23.
Fig. 1.  Botanical subsumption of Lonicera caerulea L. 
Lonicera caerulea:
Kingdom:  Plantae
 Subkingdom:  Tracheobionta – Vascular plants
  Superdivisio:  Spermatophyta – Seed plants
   Divisio:  Magnoliophyta – Flowering plants
    Class:  Magnoliopsida – Dicotyledons
     Subclass:  Asteridae
      Order:  Dipsacales
       Family:  Caprifoliaceae
        Genus:  Lonicera L. – Honeysuckle
         Species:  Lonicera caerulea L. 
    – Sweetberry honeysuckle
Fig. 2.  Caerulosides A and B.
2.2. Lipids
Blueberry honeysuckle fruit contain only 1.52 % lipids. 
The lipid fraction is mainly hydrocarbons, sterols, tria-
cylglycerols and phosphatidylcholine (Table 1a) (ref.21). 
The weight of fatty acids is 0.89 % total weight of ber-
ries. Main acids include palmitic (38.2 %), oleic (27.6 %), 
stearic (14.7 %), myristic (9.2 %), linolic (5.9 %), palmi-
toleic (2.8 %) and lauric acid (1.6 %). The entire weight 
of the unsaponiﬁ  able proportion (sterols, alcohols and 
hydrocarbons) is 0.46 % of the berries, and includes α-
amyrin (29.6 %), β-amyrin (24.7 %), stigmasterol (14.8 %) 
and ursolic acid (11.5 %) (Table 1b) (ref.24). Ursolic acid 
and its 19-hydroxy derivative pomolic acid were reported 
to inhibit proliferation and DNA synthesis in HL-60 
leukemia cell line at micromolar concentrations25. Ursolic 
acid, β-amyrin, and glucoside of β-sitosterol inhibits the 
growth of HCT 116 human colon cancer cells and PC-12 
adrenal pheochromocytoma cells at micromolar concen-
trations26.
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2.3. Other components
Fruit content includes 14.62 % dry matter21, of which 
14.8 % is soluble ﬁ  ber27. Organic acids (12.2 %) are repre-
sented by citric (3.7 %), malic (18.0 %) and others (2.4 %) 
(ref.20). 
2.4. Phenolic compounds
Small berries are one of the most important sources 
of phenolic compounds with potential health promoting 
eﬀ  ects. L. caerulea contain a huge amount of these com-
pounds. The phenolic content is dependent on the degree 
of maturity, genetic diversity, preharvest climatic, posthar-
vest storage conditions and processing20. We prepared a 
phenolic fraction from L. caerulea var. kamtschatica (4 % 
of fresh fruits) containing 33.5 % of phenolics, including 
anthocyanins (18.5 %), ﬂ  avonoids and phenolic acids21.
The polyphenols comprise a range of chemical class-
es of secondary plant metabolites that they all share the 
ability to act as chain breaking antioxidants28. Phenolic 
compounds are essential for the growth and reproduc-
tion of plants and are produced as a response to plant 
injury by pathogens. At low concentrations they also 
protect food from oxidative deterioration. At high con-
centrations they or their oxidation products may interact 
with proteins, carbohydrates and minerals29. The health 
beneﬁ  ts of polyphenols are usually linked to two proper-
ties: (i) inhibition of certain enzymes such as xanthine 
oxidase, aldose reductase, and (ii) antioxidant activity30. 
Polyphenols can protect other food components such as 
carotenoids and vitamin C and also digestive enzymes 
and gut epithelial cells from oxidation due to free radicals 
generated in stomach31, 32. 
Little is known about the bioavailability, absorp-
tion and metabolism of polyphenols in humans and it 
is likely that single groups of ﬂ  avonoids have diﬀ  erent 
pharmacokinetic properties33. Phenolics are powerful 
antioxidants in in vitro models, but there is lack of infor-
mation about whether they can remain a suﬃ   cient time 
in eﬃ   cient chemical forms in the human body29. A large 
proportion of the ingested polyphenols from berries are 
not taken up into the circulation and pass through the up-
per GIT into the large intestine where they may be trans-
formed or broken down by the indigenous microﬂ  ora34. 
Phenolic compounds are metabolized by deconjugation 
and reconjugation reactions. They are hydrolyzed to their 
free aglycones, and then they are conjugated by methyla-
tion, sulphation, glucuronidation or their combination. 
The subsequent metabolic pathway is similar to that of 
drug metabolism. Since drugs are usually administrated 
in hundreds of milligrams in one dose while dietary phe-
nolics are presented in much lower concentration, drugs 
usually saturate these pathways. When food phenolics are 
administrated at pharmacological doses, they are found 
in free forms in the blood35. Large doses are metabolized 
primarily in the liver. Small doses may be metabolized in 
the intestinal mucosa, the liver has a secondary role in 
their metabolism35. Hollman et al.36 proposed, based on 
indirect evidence, that ﬂ  avonoid glycosides actually may 
be absorbed intact in the small intestine, using sodium-de-
pendent glucose transporter 1 (SGLT1). On the one hand 
this postulate has been conﬁ  rmed37. On the other hand it 
has been demonstrated that the eﬃ   ciency of such absorp-
tion is dramatically suppressed by eﬄ   ux of at least some 
ﬂ  avonoid glycosides by the apical transporter multidrug 
resistance-associated protein 2 (MRP2) (ref.38). Some 
ﬂ  avonoid glycosides could be hydrolyzed in the small 
intestine39. If the ﬂ  avonoid glycosides are able to enter 
the intestinal epithelial cells (enterocytes), which may 
include shredded cells, they may be hydrolyzed by broad-
speciﬁ  c β-glucosidase (BSβG) (ref.40). For some ﬂ  avonoid 
glycosides, lactase phloridzin hydrolase (LPH), located 
in the brush border of the mammalian small intestine, 
Table 1. Lonicera caerulea berries a) lipid fraction b) unsaponiﬁ  able matter.
a)
Compounds Relative content (%)
Hydrocarbons+sterols 32.0
Triglycerols 27.0
Phosphatidyl choline 21.0
Free fatty acids 7.0
Phosphatidic acid, 
phosphatidyl serine + 
min. phospholipids
6.0
Digalactosyl diglycerol 4.0
Phosphatidyl ethanolamine 3.0
Hydrocarbons+sterols 3.3
b)
Compounds Relative content (%)
α-Amyrin 29.6
β-Amyrin 24.7
Stigmasterol 14.8
Ursolic acid 11.5
Triterpens 5.3
Sitosterol 4.9
Oleanolic acid 3.3
Δ7-Stigmastenol 3.3
Campesterol 2.0
Brassicasterol 0.6166  I. Svarcova, J. Heinrich, K. Valentova
could perform this hydrolysis41. It has also been shown, 
that phenolics, which have rhamnose in their molecule, 
cannot be absorbed through the small intestine. They are 
degraded by the action of rhamnosidases produced by the 
colonic microﬂ  ora29.
2.4.1. Phenolic acids
Phenolic acids form approximately one third of the to-
tal intake of plant polyphenols in the human diet42. Daily 
consumption of phenolic acids has been estimated as 25 
to 1000 mg (ref.43). They are present in free and bound 
forms in plant material. Bound phenolic acids may be 
linked through ester, ether, acetyl or other bonds42. Simple 
phenolic acids may also be formed by colonic microﬂ  ora 
from ingested ﬂ  avonoids44. 
Total content of phenolic acids in L. caerulea berries 
ranges from 2845.8 ± 141.0 to 5418.2 ± 228.0 mg · kg–1, 
dry weight (DW) (ref.45). Chlorogenic (0.42 %), caﬀ  eic 
(0.14 %) and ferulic acid (0.10 %) were the most abun-
dant in our phenolic fraction of L. caerulea var. kamts-
chatica berries; the content of protocatechuic, gentisic, 
rosmarinic, and vanillic acids was 0.08 % in total21. Other 
hydroxycinnamic acid and hydroxybenzoic acid deriva-
tives are mentioned in the literature, especially m-cou-
maric and p-coumaric. The amount of hydroxycinnamic 
acids derivatives is described as comparable to blueber-
ries or blackcurrant46. Also dimethoxycinnamic, hydroxy-
caﬀ  eic, gallic, o-pyrocatechuic, protocatechuic, salicylic, 
p-hydroxyphenylacetic and p-hydroxyphenyllactic acid are 
reported45.
Free phenolic acids stand for only a minor portion 
of phenolic acids. Their amounts ranged from 1.7 to 4.2 
% for all berries. Caﬀ  eic, ferulic and p-coumaric acids 
predominate. Free phenolic acids levels do not exceed 
taste threshold and they do not inﬂ  uence the taste of the 
berries45.
Bound phenolic acids are present in ester (69.7 %) 
form. L. caerulea again contains m-coumaric acids as the 
dominant acid. Also caﬀ  eic, ferulic, gallic, p-hydroxyphe-
nylacetic, p-hydroxyphenyllactic and vanillic acid occur 
in minor amounts. Phenolic acids bound by glycosidic 
linkages constitute 28.6 %. The majority are represented 
by hydroxycinnamic acid derivatives (61.1 %), especially 
m-coumaric. The content of ferulic, gentisic, protocate-
chuic and vanillic acids does not reach 50 mg · kg–1, DW 
(ref. 45).
Chlorogenic acid is formed by the esteriﬁ  cation of caf-
feic acid with quinic acid. It can be also degraded to caf-
feic and quinic acid by esterases produced by the colonic 
microﬂ  ora47. Caﬀ  eic acid is known as an antioxidant both 
in vitro and in vivo48. While both caﬀ  eic and chlorogenic 
acid have been reported to be absorbed in humans49, caf-
feic acid absorption is nevertheless hampered when it is 
esteriﬁ  ed with quinic acid. Caﬀ  eic acid is still listed un-
der older Hazard Data sheets as a potential carcinogen 
because of two early experiments on rats and mice. More 
recent data show that bacteria in the rat’s guts may alter 
the formation of caﬀ  eic acid metabolites. There have been 
no known adverse eﬀ  ect of caﬀ  eic acid in humans50,51. 
Ferulic acid could be absorbed by passive diﬀ  usion or by 
facilitated transport that appears not be saturated even at 
a luminal concentration of 50 μmol/l (ref.52). The absorp-
tion of ferulic acid and also free cinnamic acid are con-
trolled by the Na+/dependent carrier-mediated transport 
process in rat jejunal segments53. Some food products also 
contain oxidatively coupled product of the ferulic acid, 
the diferulic acid54. Coumaric acid is a hydroxy derivative 
of cinnamic acid. There are three isomers, o-coumaric, 
m-coumaric and p-coumaric acid, that diﬀ  er by the po-
sition of the hydroxy substitution of the phenyl group. 
p-Coumaric acid is the most abundant isomer in nature, 
has antioxidant properties55 and is believed to reduce the 
risk of stomach cancer56.
2.4.2. Flavonoids
Flavonoids are polyphenolic compounds, whose 
structure is formed by the diphenyl propane skeleton 
(C6-C3-C6). The diﬀ  erences within each group ﬂ  ow from 
variation in numbering and order of the hydroxyl groups, 
as well as the nature and extent of alkylation and glyco-
sylation of these groups. The degree of hydroxylation is 
a determinant for their tendency to degradation in the 
colon and products formed by colonic microﬂ  ora. The ab-
sence of hydroxyl group in the molecule prevents the deg-
radation of the ring structure; the degree of hydroxylation 
magniﬁ  es the tendency to degradation. The absence of the 
methyl group causes a decrease in the tendency to degra-
dation57. Food ﬂ  avonoids are usually glycosylated mostly 
with glucose or rhamnose, but galactose,   arabinose, xy-
lose; glucuronic acid and other sugars can also be found. 
The number of sugar molecules can be one, two or three 
in diﬀ  erent possible positions of the ring substitution. The 
glycosylation inﬂ  uences chemical, physical and biological 
properties of these compounds35.
The extent of absorption and bioavailability of drugs 
has long been known to be aﬀ  ected by membrane transport-
ers, mainly eﬄ   ux transporters, in addition to   metabolism. 
The traditional eﬄ   ux transporter for drugs, e.g. P-glyco-
protein, does not seem to be involved in the transport of 
ﬂ  avonoids. Other transporters have been found to play a 
role, e.g. the absorptive transporter SGLT1 (ref.38), the 
absorptive monocarboxylate transporter (MCT), MRP2, 
but probably also other MRP isoforms, for glucuronide 
and sulphate conjugates38, 58.
The metabolism of ﬂ  avonoids was initially described 
to be mediated by cytochrome P450 (CYP) enzymes59 in 
liver microsomes from induced rats and from humans, but 
it has never been shown to be important in vivo or in in-
tact cells, where conjugative metabolism may be expected 
to compete with oxidation60. Glucuronic acid conjugates 
of ﬂ  avonoids have been well-documented with respect to 
both the molecular site of glucuronidation and the UD
P-glucuronyltransferase (UGT) isoforms involved61. One 
of the tea ﬂ  avonoids, epicatechin gallate (ECG), showed 
only sulphate conjugation62. Other metabolic pathways 
include O-methylation by soluble catechol-O-methyltrans-
ferase (COMT) (ref.63) or by bacterial enzymes. Bacteria 167 Berry fruits as a source of biologically active compounds: the case of Lonicera caerulea
Fig. 3.  Chemical structures of a) quercetin; b) apigenin; 
c) epicatechin.
from faecal ﬂ  ora may be responsible for the hydrolysis of 
ﬂ  avonoids glycosides as well as ﬂ  avonoid glucuronides 
and sulphates. The reaction proceeds via degradation of 
the ﬂ  avonoid backbone into numerous phenolic and car-
boxylic acid products64, as well as carbon dioxide65. Many 
of these products are absorbed and can be detected in 
human urine64. Other types of metabolites are those result-
ing from oxidation by reactive oxygen species (ROS)66. 
Covalent binding of oxidized quercetin to DNA and cel-
lular protein has been demonstrated in human cells67.
2.4.2.1. Flavonols, ﬂ  avons and ﬂ  avan-3-ols
Flavonols (e.g. quercetin) have a similar C-ring struc-
ture with a double bond in the 2–3 position as ﬂ  avones 
(e.g. apigenin). Flavones lack a hydroxyl group at the 
3-position. Flavan-3-ols (e.g. epicatechin) lack a double 
bond in the 2–3 position. Quercetin (0.1 % of the phe-
nolic fraction), its 3-glycoside (0.06 %) and 3-rutinoside 
(0.75 %) and minor quantities of epicatechin and apigenin 
were found in our L. caerulea var. kamtschatica phenolic 
fraction21.
Quercetin is one of the most extensively studied ﬂ  a-
vonoids apropos its anticancer activity because of its 
prevalence among fruits and vegetables (Fig. 3) (ref.68). 
Quercetin glucosides are resistant to hydrolysis by HCl in 
stomach69 and the absorption occurs in the small intestine 
into enterocytes probably via active transport70,71. They 
can be methylated into isorhamnetin immediately after 
absorption in the human body. Quercetin rutinosides are 
absorbed from the colon following the deglycosylation71. 
After intravenous dose, quercetin can be detected in urine, 
in particular after hydrolysis with β-glucuronidase/aryl 
sulphatase72. The main route of quercetin excretion is as 
carbon dioxide, 23 – 81 % of the dose, measured by trap-
ping exhaled air73. Apigenin is a nontoxic dietary ﬂ  avonoid 
that has been shown to have anti-tumour and anti-inﬂ  am-
matory activities (Fig. 3). Apigenin can block the forma-
tion of uric acid leading to beneﬁ  cial eﬀ  ects in gout74. 
Catechin and epicatechin are epimers, with (-)-epicatechin 
and (+)-catechin being the most common optical isomers 
found in nature (Fig. 3) (ref.75). Epicatechin can reduce 
the risk of four of the major health problems: stroke, heart 
failure, cancer and diabetes76. Acylated ﬂ  avonoids, such as 
epicatechin are reported to be absorbed without deconju-
gation and hydrolysis77.
2.4.2.2. Anthocyanins
Anthocyanins are secondary plant metabolites, deriva-
tives of 2-phenylbenzopyrylium, generally found in glyco-
sidic forms78–80. The aglycones (anthocyanidins) are rarely 
found in fresh plants. They occur as 3-glycosides and 3,5-
diglycosides linked with glucose, galactose, rhamnose or 
arabinose78. Anthocyanins represent the most important 
group of water-soluble pigments, responsible for the blue, 
purple and red colour of many plant tissues due to their 
ability to associate into complexes characterized by higher 
absorbance of light lengths, co-pigmentation and forma-
tion of complexes with metals. In aqueous solution, an-
thocyanins exist in a number of diﬀ  erent molecular forms 
that are in dynamic equilibrium depending mostly on pH 
(Fig. 4). The red ﬂ  avylium cation is the most abundant 
molecular form at pH < 2. As the pH increases, there is 
rapid loss of a proton to generate the blue quinonoidal 
structure. At the same time, much slower hydration of the 
ﬂ  avylium cation occurs to yield the colourless hemiketal 
form that further tautomerises to generate the chalcone 
form81. The positively-charged oxonium anthocyanin 
form may not be aﬀ  ected by MRP2 eﬄ   ux, which seri-
ously limits the absorption of other ﬂ  avonoid glycosides38. 
Anthocyanins seem to be able to be absorbed intact as 
glycosides82. However, the proportion of anthocyanins 
absorbed and excreted in the urine appears to be quite 
small, perhaps much less than 0.1 % of the intake83. The 
clearance of anthocyanins from the circulation is rapid; 
very little is generally detected in the plasma 6 h after 
administration82. Some anthocyanins can be metabolized 
to colourless forms, oxidized, or degraded into other com-
pounds. Researchers have also found that no glycoside 
hydrolysis takes place during digestion84. The absorption 
of anthocyanins without removal of glycoside has also 
been demonstrated85.
Anthocyanins and proanthocyanidins have antibacte-
rial properties as well as the ability to inhibit adhesion 
of bacteria to mucosal membrane of urinary tract86. 
Anthocyanins also act as anti-inﬂ  ammatory and anti-muta-
genic agents and provide cardioprotection by maintaining 
vascular permeability4. The ability to regulate the perme-
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Fig. 4.  Various anthocyanin forms existing in aqueous solutions depending on pH (gly = glycoside).
ability of capillary vessels has become the basis for their 
deﬁ  nition as vitamin P. They show protection against hep-
atitis A and B and also against paracetamol hepatotoxic-
ity87. Berry extracts rich in anthocyanins have been linked 
to protective eﬀ  ects including the modulation of age-re-
lated neurological dysfunctions and improved   resistance 
of red blood cells against oxidative stress in vitro88.
Anthocyanins are very good antioxidants due to the 
presence of hydroxyl groups in position 3 of the C ring, 
which can chelate metal ions (Fe, Cu), and 3' and 4' of the 
B ring. Antioxidant activity is also increased by acylation 
of sugar residues with aromatic hydroxy acids89. These 
compounds have higher antioxidative activities than vita-
min E, ascorbic acid or β-carotene79.
The major anthocyanins in L. caerulea fruit are the 
glucosides and rutinosides of cyanidin, peonidin, dephi-
nidin and pelargonidin21 (Fig. 5). Quantities of these 
compounds vary depending on a number of the factors46. 
Table 2 shows a comparison of L. caerulea phenolic frac-
tion anthocyanin content with those of Vaccinium macro-
carpon90 and Vitis vinifera91.
Cyanidin is the most common anthocyanidin, with a 
3', 4'-dihydroxylation of the B ring, present in 90 % of 
fruits92. Wu et al.83 detected the methylated form of an-
thocyanins in human urine after consumption of elder-
berries and blueberries. The cyanidin glycosides tend to 
have higher antioxidant capacity than peonidin or malvi-
din glycosides likely due to the free hydroxyl groups on 
the 3' and 4' positions of cyanidin93. The key diﬀ  erence 
compared to other ﬂ  avonoid glucosides, is that cyanidin-
3-glucoside appears to be absorbed after oral ingestion, 
although to a limited extent38. Cyanidin-3-rutinoside from 
sweet cherry exhibited cyclooxygenase I and II inhibitory 
activities94. It showed potential in the treatment of diabe-
tes, obesity, hyperlipidemia95 and B and C type viral hepa-
titis96. Delphinidin may preserve endothelium integrity and 
protect against endothelial cell apoptosis97. Delphinidin, 
malvidin and petunidin are metabolized in the liver 
through the catechol-O-methyltransferase reaction in the 
3' position83. Pelargonidin itself displays an orange red 
color. Pelargonidin-3-monoglucoside, isolated from frozen 
strawberries, protected the amino acid tyrosine from the 
highly reactive oxidant peroxynitrite, inhibited the growth 
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Table 2. Content of anthocyanins in Lonicera caerulea, Vaccinium macrocarpon and Vitis vinifera extracts.
Compounds  Relative content (% w/w)
L. caerulea21 V. macrocarpon90 V. vinifera91
Cyanidin-3-arabinoside – 5.5 –
Cyanidin-3-galactoside – 7.1 –
Cyanidin-3-glucoside 60.0 12.3 7.0
Cyanidin-3(6'-acetyl)-glucoside – – 1.8
Cyanidin-3,5-diglucoside 9.9 – –
Cyanidin-3-pentoside – 2.9 –
Cyanidin-3-rutinoside 7.3 – –
Delphinidin – 1.8 –
Delphinidin-3-glucoside 1.2 – 3.7
Delphinidin-3-rutinoside 2.0 –
Pelargonidin-3-glucoside 3.3 – –
Pelargonidin-3,5-diglucoside 0.6 – –
Pelargonidin-3-rutinoside 0.1 – –
Peonidin-3-arabinoside – 5.7 –
Peonidin-3-galactoside – 10.2 –
Peonidin-3,5-digalactoside – 24.1 –
Peonidin-3-glucoside 5.8 60.7 18.7
Peonidin-3,5-diglucoside 8.1 –
Peonidin-3(6'-coumaroyl)-diglucoside – – 1.2
Peonidin-3-rutinoside 0.5 – –
Petunidin-3-glucoside – – 10.7
Malvidin-3-glucoside – – 64.6
Malvidin-3(6'-acetyl)-glucoside – – 1.0
Malvidin-3(6'-caﬀ  eoyl)-glucoside – – 1.8
Malvidin-3(6'-coumaroyl)-glucoside – – 2.5
Total anthocyanins  100 100 100
of Escherichia coli and Staphylococcus aureus, and exerted 
both a stimulatory and inhibitory eﬀ  ect on Lactobacillus 
casei culture. The stimulation may be due to a decrease in 
the oxidation-reduction potential of the media aﬀ  ected by 
the pigment, and/or the ability of the organism to split the 
β-glycosyl bond and use the glucose moiety98. Peonidin has 
been patented for use as food colouring agent99.
2.4.3. Proanthocyanidins
Proanthocyanidins (condensed tannins) are oligomeric 
and polymeric end products of the ﬂ  avonoid biosynthetic 
pathway and are metabolized to anthocyanidins79. They 
can be considered as the ﬁ  fth class of plant biopolymers 
besides polynucleotides, proteins, lignins and polysaccha-
rides. As a class, proanthocyanidins can be complex in 
structure and composition, featuring various ﬂ  avan-3-ols 
(most commonly catechin, epicatechin, and galloylated 
catechins) linked together in diﬀ  erent ways. Berry proan-
thocyanidins are primarily dimers, trimers and other 
oligomers100. These molecules may contain two types of 
linkages between epicatechin units. The B-type (4β → 8) is 
widely found in apples and grapes and A-type (4β → 8 and 170  I. Svarcova, J. Heinrich, K. Valentova
L. caerulea phenolics, as secondary plant metabolites, 
have been shown to provide defence against oxidative stress 
from endogenous ROS and free radicals111. Tumor inhibi-
tion by the berries is likely to involve synergic activities be-
tween its phytochemicals, including ﬂ  avonols (quercetin), 
proanthocyanidins and others and to be primarily based 
on reducing oxidation of lipoproteins, improving antioxi-
dant status and lipid levels and   mitigating the eﬀ  ect of oxi-
dative stress and inﬂ  ammation on the vascular system112. 
Phenolics protect cardiomyocytes after ischemic episodes 
by inhibition of free radical formation in the process of 
reperfusion113. These compounds are able to reduce nitric 
oxide synthase activity and nitric oxide (NO) level114. They 
inhibit the cyclooxygenase activity, adhesion and reaction 
of leukocytes with endothelial cells, degranulation of 
mast cells and decrease in the level of interleukin (IL)-2, 
interferon (INF)-γ and tumor necrosis factor (TNF)-α 
(ref.115). Polyphenolics have been regarded as a potential 
novel, safe and nontoxic strategy for the modulation of 
inﬂ  ammation dependent on the nuclear factor (NF)-κB 
pathway27. An extract of L.   caerulea showed signiﬁ  cant 
anti-inﬂ  ammatory eﬀ  ects on endotoxin-induced uveitis in 
rat. The possible mechanisms for this eﬀ  ect may depend 
especially on its ability to inhibit activation of NF-κB and 
the subsequent production of proinﬂ  ammatory mediators 
such as TNF-α, prostaglandin (PG)-E2 and NO (ref.27).
Berry anthocyanins act as novel cardioprotectants by 
maintaining vascular permeability, reducing inﬂ  amma-
tory responses and platelet aggregation, and oﬀ  er superior 
vascular protection compared to other cardioprotective 
drugs116, 117. Bioactive compounds from L. caerulea have 
been also demonstrated in in vitro models to inhibit the 
oxidation of lipoproteins. A recent study of ours showed 
inhibition of copper-induced lipoprotein oxidation by 
a phenolic fraction of L. caerulea var. kamtschatica118. 
Reduction of atherosclerotic plaques by polyphenolics has 
been found in animal models; reduction of carcinogenesis 
was observed in vitro. Epicatechin76 and anthocyanins, es-
pecially delphinidin, may preserve endothelium integrity 
whose damage can lead to the development of athero-
sclerosis and also cancer97. Some L. caerulea compounds 
can block mutagenesis by chemical carcinogens and en-
dogenous mutagens and have been shown to modify the 
process of uncontrolled cell proliferation and apoptosis 
in vitro119. These phytochemicals may exert their anticar-
cinogenic eﬀ  ect by modulating the enzyme systems that 
metabolize carcinogens or procarcinogens to genotoxins. 
For example CYP activity can be induced or inhibited by 
ﬂ  avonoids. Ellagic acid inhibits mutagenesis and carcino-
genesis by acting on both CYP xenobiotic metabolism and 
several phase 2 detoxifying enzymes120. Berry extracts can 
protect against carcinogenesis also in animal models121. 
Numerous reports shows quercetin ability to inhibit pro-
liferation of cancer cell lines in vitro, including breast, 
colon, pancreas cancer, and leukemia122. Its mechanism 
of action includes induction of apoptosis123, inhibition 
of epidermal growth factor receptor expression and as-
sociated tyrosine kinase activity122, reduced expression of 
Ras protein in colon cancer cells and primary colorectal 
tumors124, increased expression of endogenous inhibitors 
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2β → O →7) found in cranberries can inhibit adherence 
of uropathogenic P-ﬁ  mbriated Escherichia coli (Fig. 6) 
(ref.101, 102). The stereochemistry of the linkage at C4 may 
be α or β103. The major function of proanthocyanidins in 
plants is to provide protection against microbial patho-
gens, insect pests and larger herbivores. Their deposition 
in the endothelial layer of the seed coat appear to be an 
example of a pre-formed protective barrier104. Salmonella, 
Staphylococcus, Helicobacter and Bacillus are the most 
sensitive bacteria to the berry phenolics. In addition, the 
growth of Escherichia, Clostridium and Campylobacter spe-
cies but not Lactobacillus and Listeria species are inhib-
ited105. The main mechanisms of action are destabilization 
of cytoplasmic membrane, permeabilization of plasma 
membrane, inhibition of extracellular microbial enzymes, 
direct actions on microbial metabolism and deprivation of 
the substrates required for microbial growth106.
3.  TRADITIONAL USE AND PUTATIVE 
HEALTH BENEFITS 
L. caerulea berries have long been harvested from 
wild plants in regions of Russia, China and Japan where 
superior edible forms are native. Recently, research in 
Russia and Japan has resulted in cultivars being selected 
for commercial production because of its very early matu-
rity, unique ﬂ  avour and health beneﬁ  ts that have long been 
acknowledged in Russia16. Recent research has supported 
some of the folkloric claims for the therapeutic uses of 
blue honeysuckle berries in atherosclerosis, hypertension, 
gastrointestinal disorders and bacterial infection. The 
main beneﬁ  cial eﬀ  ect is due to the presence of vitamin C 
and high levels of polyphenolics 16, 107–110. 171 Berry fruits as a source of biologically active compounds: the case of Lonicera caerulea
of matrix metalloproteinases125 and phytoestrogenic ac-
tivity involving interaction with the estrogen α- and β-re-
ceptors of human breast cancer MCF-7 cells68. Cyanidin 
and its 3-glycoside reduce oxidant-induced DNA strand 
breakage in normal human lymphocytes ex vivo and are 
as potent chemoprotectants as the ﬂ  avonols, quercetin 
and myricetin. Cyanidin-3-rutinoside and cyanidin-3-glu-
coside suppress cancer cell metastasis by inhibiting the 
motility adhesiveness and invasiveness of metastatic hu-
man lung cancer cell lines A579 (ref.126). Cyanidin and 
a mixture of several of its glycosides dose-dependently in-
hibited HCT 116 and HT 29 colon cancer cell growth127. 
Delphinidin, malvidin and petunidin also inhibited pro-
liferation of cancer cells derived from various tissues in-
cluding colon, breast, blood and lung at high micromolar 
concentrations128. Peonidin has shown potent inhibitory 
and pro-apoptotic eﬀ  ects on cancer cells in vitro, notably 
human metastatic breast cancer cells99. p-Coumaric acid 
is believed to reduce the risk of stomach cancer by reduc-
ing the formation of carcinogenic nitrosamines56. Also 
caﬀ  eic acid and epicatechin have been shown to act as an 
inhibitor of carcinogenesis48,76. Wild and cultivated berry 
proanthocyanidin fractions demonstrated antiproliferative 
eﬀ  ects on two models of prostate cancer: an androgen-sen-
sitive (LNCaP) and more aggressive androgen-insensitive 
cell line (DU145) (ref.129).
Several berry derivatives have also potent anti-angio-
genesis properties in vitro by altering vascular endothe-
lial growth factor (VEGF) expression and invasiveness. 
Berry extracts can inhibit hydrogen peroxide and TNF-α 
induced VEGF expression in these cells and also inhibit 
angiogenesis in animals130. For example apigenin inhibits 
expression of VEGF in human ovarian cancer cells74.
Polyphenolic fractions from plants can display insu-
lin-like eﬀ  ects by reducing blood glucose levels after food 
intake131. The main eﬀ  ect may be due to inhibition of 
starch degradation within the gastrointestinal tract (GIT) 
by inhibiting α-glucosidase/maltase activity132. It has been 
shown, that anthocyanins, especially diacylated forms 
owing to intestinal pH, inhibit α-glucosidase   activity and 
can reduce blood glucose levels after starch-rich meals, 
a proven clinical treatment for controlling diabetes mel-
litus type II (ref.132, 133). Anthocyanins can directly induce 
insulin secretion from pancreatic cells in ex vivo   models, 
but this eﬀ  ect may be disregarded because of its low se-
rum bioavailability31, 134. Cyanidin-3-glucoside, quercetin, 
ferulic acid, peonidin-3-glucoside and tocopherol, in this 
order, showed signiﬁ  cant inhibitory activity against al-
dose reductase activity135. Cyanidin-3-rutinoside   inhibited 
α-glucosidase from baker’s yeast in a dose-dependent man-
ner136. It can lead to a reduction in glucose absorption 
and therefore the rise of postprandial hyperglycemia can 
be attenuated94. Berry anthocyanins appear to beneﬁ  t 
vision in several ways in diabetes, including improving 
night vision by enhanced generation of retinal pigment, 
increasing circulation within the capillaries of the retina, 
decreasing macular degeneration and diabetic retinopathy, 
and improving or preventing glaucoma and cataracts137.
A range of berry polyphenols can inhibit protease ac-
tivities at levels which may aﬀ  ect protein digestion in the 
GIT. Soluble proanthocyanidins can inhibit pancreatic 
and gastric lipase activity and therefore would be a tar-
get in the treatment of obesity133. Berries have also been 
shown to reverse age-related and oxidative stress-induced 
decline in brain function in rats138.
CONCLUSION
Lonicera caerulea berries contain 7.20 % saccharides, 
1.52 % lipids, 14.62 % dry matter, 12.2 % organic acids 
and 4 % phenolics, containing 33.5 % of phenolics, includ-
ing anthocyanins (18.5 %), ﬂ  avonoids and phenolic acids. 
The major anthocyanins in L. caerulea fruit are gluco-
sides and rutinosides of cyanidin, peonidin, dephinidin 
and pelargonidin. These berries seem to be prospective 
sources of health supporting phytochemicals that exhibit 
beneﬁ  cial activities such as anti-adherence, antioxidant 
and chemoprotective, thus they may provide protection 
against a number of chronic conditions, e.g. cancer, dia-
betes mellitus, tumor growth or cardiovascular diseases. 
These plants can be cultivated in European climatic condi-
tions and therefore are a suitable source of economically 
accessible nutraceutical preparations.
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